Iterum Therapeutics Plc (NASDAQ:ITRM) concluded the trading at $1.13 on Friday, April 04 with a fall of -3.42% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $1.17 and 5Y monthly beta was reading 2.876 with its price kept floating in the range of $1.09 and $1.24 on the day. Considering stock’s 52-week price range provides that ITRM hit a high price of $3.02 and saw its price falling to a low level of $0.81 during that period. Over a period of past 1-month, stock came subtracting -17.52% in its value.
With its current market valuation of $39.08 million, Iterum Therapeutics Plc is set to declare its quarterly results on 2025-Feb-06. Analysts are in estimates of 0 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to 0 for current year with estimates of that growing to 0 in next year.
In contrast, when we review ITRM stock’s current outlook then short term indicators are assigning it an average of 100% Sell, while medium term indicators are categorizing the stock at an average of 50% Sell. Long term indicators are suggesting an average of 50% Sell for it.
According to ratings assigned by 1 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 0 of them are recommending Iterum Therapeutics Plc (ITRM) as a Hold, while 1 are in view that stock is a Buy. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 0, whereas 0 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the ITRM stock which is currently positioned at 0. It further provides that stock’s current price level is -14.73% away from its 20-day simple moving average and is -19.50% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 29.98 while volatility remained at 8.86% over the past week which changes to 6.47% when measuring it over the past month. Beta is valued at 2.86, while measure of average true range or ATR is currently at 0.09.
Having a second look at Iterum Therapeutics Plc (NASDAQ:ITRM) provides that stock’s average daily trading volume for 3 months was 455.83K, while it jumped to 311350 when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 34.58 million.
The percentage of outstanding shares held by the insiders is 2.19% while it is 2.56% for the institutional holders. The figures also indicate that as of 2025-03-14, number of stock’s short shares was 1.53 million which implies a short ratio of 5.19. This shows down a 453.00 of Short Interest in company’s outstanding shares on the day. In March the standing of shares short improved as it was 1.85 million in the previous month. Subtraction of -36.16% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.
